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Background: Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally
advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local
progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2
is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser
nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase
(stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2).
Methods: Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles
of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible
for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-
chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise
170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose
(arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E).
Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins.
Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival
(nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment
compliance, and CA19–9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme.
Discussion: SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen.
Trial registration: Eudract No: 2013–004968-56; ClinicalTrials.gov: NCT02024009.
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Consolidation chemoradiation following induction chemo-
therapy is a treatment option for locally advanced pancre-
atic cancer (LAPC). The radiosensitiser capecitabine is
commonly combined with radiotherapy doses of 50.4–54
Gy in 28–30 fractions [1]. However, current chemoradia-
tion regimens have not demonstrated superior overall
survival (OS) over chemotherapy alone [2, 3], local failure
occurs in 40–60% of cases despite chemoradiation [4–6],
and tumours are rarely down-staged to resectibility [1] or
achieve pathological complete responses [5, 7]. Chemoradi-
ation must be optimised to improve these outcomes,
particularly as studies have shown that nearly one-third of
patients with LAPC die due to local progression rather
than systemic spread [8], and local failure may be a pre-
dictor of early mortality (hazard ratio [HR] = 2.15; 95%
confidence interval (CI): 1.23–3.75, [4]).
Rationale and feasibility of radiotherapy dose escalation
Pancreatic cancer is a radioresistant tumour surrounded
by at-risk radiosensitive organs: the gastrointestinal
tract, liver, and kidneys. A radiation dose range of
50.4–54 Gy in 28–30 fractions has traditionally been
used to compromise between efficacy and toxicity. Al-
though radiotherapy dose escalation remains challenging,
modern-day technical radiotherapy advancements like
intensity-modulated radiotherapy (IMRT) and image-
guided radiotherapy allow precise delivery of radiotherapy
while relatively sparing the organs at risk [9–11].
A small retrospective study in LAPC patients showed
that a radiotherapy dose ≥54 Gy, versus < 54 Gy, was
associated with improved OS (11.3 months vs 6.8
months, p = 0.089) [12]. A phase I/II radiotherapy dose-
intensification study explored escalating the dose per
fraction from 50 to 60 Gy in 25 fractions, concurrent
with gemcitabine 1000mg/m2 weekly in 50 patients with
LAPC [9]. The study recommended a phase II dose of
55 Gy in 25 fractions and reported a median OS time of
14.8 months (95% CI: 12.6–22.2) and two-year OS rate
of 30% (95% CI: 17–45%). Twelve participants under-
went resection with a median OS time of 32 months. A
planning study demonstrated that the radiation dose can
be escalated to 72 Gy in 36 fractions using IMRT or pro-
ton therapy, based on the relationship between the gross
tumour volume (GTV) and gastrointestinal tract [13].
Rationale and evidence for nelfinavir as a radiosensitiser
Nelfinavir is a human immunodeficiency virus protease
inhibitor traditionally used to manage acquired immune
deficiency syndrome. Preclinical data has shown that
nelfinavir and some other protease inhibitors inhibit
phospho-inositol-3 kinase and downregulate Akt phos-
phorylation, leading to radiosensitisation [14–17]. As the
Akt pathway is overactive in tumours but not normaltissue, radiosensitisation is selective without aggravating
radiotherapy-mediated normal tissue damage. This
radiosensitisation effect is even seen in KRAS-mutant
pancreatic cell lines [14], which is highly relevant in
clinical practice as > 90% of pancreatic tumours are
KRAS-mutant. Inhibiting this pathway also normalises
tumour vasculature, increases vascular flow and perfu-
sion, and reduces hypoxia in tumour xenografts [18, 19].
Patients on nelfinavir who receive radiotherapy do not
show increased acute toxicity [20]. Two early phase
studies, ARC-I and ARC-II, prospectively tested nelfina-
vir with chemoradiation in pancreatic cancer. ARC-I was
a phase I trial of 12 patients with LAPC who were
treated with an upfront chemoradiation schedule of
radiotherapy dose of 59.4 Gy in 33 fractions and 1250
mg nelfinavir twice-daily (from 3 days before the start of
radiotherapy, until the final day of radiotherapy).
Chemotherapy (30 mg/m2 cisplatin and 200–300 mg/m2
gemcitabine) was delivered on days 1, 8, 22, and 29 [21].
The study reported a Common Terminology Criteria for
Adverse Events (CTCAE) grade 3–4 non-haematological
toxicity rate of 16.7%. Half of the participants showed a
metabolic complete response on FDG-PET, and a
complete resection margin was achieved in six partici-
pants. The median OS time was 18months. The recom-
mended phase II dose for gemcitabine in the combination
was 300mg/m2.
ARC-II, a single-arm phase II study, tested the ARC-I
regimen in another 23 patients [22] and reported prom-
ising outcomes (one-year OS rate 73.4, 90% CI: 54.5–
85.5%; median OS time 17.4 months, 90% CI: 12.8–18.8).
Although there was a high incidence of grade 3 or above
gastrointestinal toxicity (nausea and vomiting 21.7%,
diarrhoea 21.7%), nearly 75% of participants received the
full radiotherapy dose and 87% received at least 80% of
the intended nelfinavir dose. The gemcitabine+cisplatin
combination chemotherapy and the large radiation field
(which included elective nodal irradiation) may have
contributed to gastrointestinal toxicity. Neither the
gemcitabine+cisplatin combination regimen nor use of
such large radiation fields are standard in current-day
pancreatic chemoradiation.
Given the need for optimised chemoradiation in LAPC
and nelfinavir’s promising radiosensitising effects in
pre-clinical and early phase clinical trials, SCALOP-2
aims to optimise the chemoradiation regimen for man-
aging inoperable LAPC by increasing the radiotherapy
dose intensity and/or adding nelfinavir as an additional
radiosensitiser in a randomised setting. As nelfinavir has
not been combined with capecitabine-based chemoradia-
tion for pancreatic cancer before, a nelfinavir dose-
finding phase (stage 1) was included. Stage 2 investigates
two co-primary questions: 1) does increasing the radio-
therapy dose improve the 12-month OS rate (radiotherapy
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chemoradiation improve progression-free survival (PFS)
(nelfinavir question). We report the study protocol
(version 5.0, 31 July 2015 (Stage 1); version 6.0, 10
October 2017 (Stage 2)).
Methods
Study design and participants
Stage 1 of SCALOP-2 was a single-arm, dose-finding
study of nelfinavir with capecitabine-chemoradiation
using the rolling-six design [23]. Three nelfinavir dose
levels were planned for investigation. Stage 2 com-
menced after the maximum tolerated dose of nelfinavir
was determined in Stage 1. Stage 2 is a multi-centre,
open-label, randomised 2 × 2 factorial + 1, phase II clin-
ical trial investigating safety and efficacy (Fig. 1). Recruit-
ment has opened and up to 30 UK centres are planned.Fig. 1 Schematic for Stage 2 of SCALOP-2. Legend: Stage 1 follows the flow
Abbreviations: GEMABX = gemcitabine and nab-paclitaxel; Nelf = nelfinavir;Entry criteria at registration include inoperable disease,
histologically and/or cytologically proven LAPC, World
Health Organisation (WHO) performance status of 0 or 1,
and written informed consent (obtained at site via consent
forms). After induction chemotherapy, participants are eli-
gible for post-induction treatment if they have responding
or stable disease after three cycles of chemotherapy by Re-
sponse Evaluation Criteria in Solid Tumours (RECIST)
1.1, WHO performance status 0 or 1, adequate liver and
renal function, ≤10% weight loss from baseline, and the
tumour can be encompassed by a radically treatable
radiotherapy volume (areas of known predilection for
metastases). Table 1 lists the full entry criteria.
Randomisation and stratification
For stage 2, participants eligible for post-induction
therapy are randomised in a 1:1:1:1:1 ratio to one of fivechart as for Stage 2 Arm A. Nelfinavir dose is determined in Stage 1.
Cape = capecitabine; Gy = Grays; # = fractions
Table 1 Participant eligibility criteria for trial registration
Registration inclusion criteria Registration exclusion criteria
1. Aged 18 years or over
2. Histologically or cytologically proven carcinoma of the pancreas
3. Locally advanced, non-metastatic inoperable disease as per National
Comprehensive Cancer Network criteria. The following types of inter-
ventions are allowed:
a. Palliative bypass procedure
b. Common bile duct stenting
4. Primary pancreatic lesion 6 cm or less in diameter (taken from scan
results)
5. World Health Organisation performance status 0–1
6. Adequate haematological function: neutrophils ≥1.5 × 109/L, platelets
≥100 × 109/L
7. Adequate liver function tests:
a. Serum bilirubin ≤1.5 x ULN. In participants who have had a recent
biliary drain and whose bilirubin is improving, a value of ≤3 x ULN is
acceptable, however treatment should not start unless Bilirubin is
≤1.5 x ULN.
b. AST and/or ALT ≤3 x ULN.
8. Adequate renal function: GFR≥ 45mL/min using a validated creatinine
clearance calculation (e.g. Cockcroft-Gault, Wright formula, or as per
local standard).
If the calculated creatinine clearance is less than 45 mL/min, GFR should
be assessed using a more formal method, e.g. 24 h clearance or an
isotopic clearance method to confirm GFR≥ 45mL/min in order for the
patient to be eligible for the study. This is optional and should only be
carried if part of standard care.
9. Written informed consent obtained
10. Women of child-bearing potential must have negative serum or urine
pregnancy test within 14 days prior to registration, must agree to use
a highly effective contraception method during GEMABX treatment
and for 30 days after last administration of GEMABX and to use an ac-
ceptable contraception method during chemoradiotherapy and for 6
months after completion of all treatment.
11. Male patients must be surgically sterile or must agree to use a
condom during GEMABX treatment and for 90 days after last
administration of GEMABX, and to use a condom during
chemoradiotherapy and for three months after completion of
chemoradiotherapy.
1. Primary resectable cancer of the pancreas.
2. Distant metastases
3. Pregnant or breast-feeding patients.
4. Any evidence of severe uncontrolled systemic diseases including
uncontrolled coronary artery disease, myocardial infarction or stroke
within the last 6 months, any major systemic or psychiatric co-
morbidities or any other considerations that the investigator judges
might impact on patient safety or protocol compliance and achieve-
ment of the study aims.
5. Previous malignancies in the preceding three years except for:
a. In situ cancer of the uterine cervix
b. Adequately treated basal cell skin carcinoma
c. Adequately treated early stage non-pancreatic malignancy in
complete remission for at least three years
6. Renal abnormalities including adult polycystic kidney disease or
hydronephrosis or ipsilateral single kidney (i.e. functioning right kidney
for head tumours; left kidney for tail tumours) that may preclude upper
abdominal radiotherapy without damaging functional kidneys.
7. Previous radiotherapy to upper abdomen
8. Recurrent cancer following definitive pancreatic surgery
9. Lymphoma or neuroendocrine tumours of the pancreas
10. Known haemophilia A and B, chronic hepatitis type B or C.
11. Other experimental treatment six weeks or less prior to registration
into this study (including chemotherapy and immunotherapy).
12. Known hypersensitivity to any of the investigational medicinal
product or any of their excipients e.g. hypersensitivity to food
products containing albumin.
13. Known dihydropyrimidine dehydrogenase deficiency
14. Known galactose intolerance, Lapp-lactose deficiency or glucose-
galactose malabsorption
15. History of severe unexpected reaction to fluoropyrimidine therapies
16. If the following concomitant medications cannot be discontinued
temporarily during the CRT phase then the patients cannot enter the
trial:
a. Sorivudine and analogues e.g. brivudine
b. Methotrexate.
c. Allopurinol and dipyridamole
17. Known HIV positive disease (but routine screening for HIV is not required)
abbreviations: GEMABX gemcitabine and nab-paclitaxel
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element. Minimisation factors are centre, WHO per-
formance status (0 or 1), and disease location (head or
body/tail). Randomisation is performed centrally by the
Oncology Clinical Trials Office (OCTO), University of
Oxford, using a computer-based algorithm to conceal
allocation and assigned via the OpenClinica database
system.
Interventions
Induction gemcitabine and nab-paclitaxel chemotherapy
All registered patients receive three cycles of gemcita-
bine and nab-paclitaxel (GEMABX) induction chemo-
therapy: 125mg/m2 nab-paclitaxel intravenously for 30
min, then 1000mg/m2 gemcitabine intravenously for 30
min, both on day 1, 8, and 15 of a 28-day cycle. Those
eligible for post-induction therapy have a fourth cycle of
GEMABX chemotherapy whilst radiotherapy is planned.
Participants ineligible for post-induction therapy are
treated at the investigator’s discretion and continue to
contribute treatment and outcome data.Post-induction therapy
Stage 1 participants received 50.4 Gy radiotherapy in 28
fractions over 5.5 weeks, with capecitabine (830 mg/m2
twice-daily taken orally on radiotherapy days) and nelfi-
navir. Nelfinavir was started 7 days before radiotherapy
and taken orally twice-daily until the last day of chemo-
radiation. The nelfinavir dose depended on the assigned
dose cohort: 750 mg, 1000mg (the starting dose), or
1250 mg. The dose level was assigned by the safety
review committee, following the rolling-six design. If
radiotherapy was interrupted for reasons other than
weekends, nelfinavir was also interrupted for that time.
Nelfinavir and capecitabine compliance was monitored
by review of patient diary cards.
Stage 2 participants receive post-induction therapy as
per their allocated randomised arm. Participants in arms
A and B receive 50.4 Gy radiotherapy in 28 fractions
over 5.5 weeks, and in arms C and D 60 Gy radiotherapy
in 30 fractions over 6 weeks. Participants in arms A-D
also receive 830mg/m2 capecitabine twice-daily taken
orally on radiotherapy days. Participants in arms A and
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determined in stage 1). Participants in arm E do not
receive chemoradiation, but continue GEMABX chemo-
therapy (total 6 cycles). Nelfinavir and capecitabine
compliance will be monitored by review of patient diary
cards.
Radiotherapy
The GTV includes macroscopic pancreatic tumours with
nodes > 1 cm on the short axis diameter. Prophylactic
nodal irradiation is not acceptable. 4D planning is pre-
ferred, in which a composite GTV (GTV_C) is created
from volumes outlined on the 3D CT scan and the 4D
scan’s inhale and exhale phases. The clinical target
volume (CTV_4D) is an expansion of 0.5 cm around the
GTV_C, edited off the gastrointestinal tract. The
planned target volume for the standard-dose arm
(PTV5040) is a 0.5 cm expansion around the CTV_4D.
For the high-dose arm, a PTV5400 (volume treated to
54 Gy, which is the CTV_4D with a 0.5 cm circumferen-
tial margin) and a simultaneous integrated boost (SIB)
volume (PTV6000, identical to GTV_C) are created. If
the 4D scan is not undertaken or fails, the CTV_3D isTable 2 Radiotherapy dose constraints
Description Naming Convention
PTV
High dose radiotherapy arms
PTV6000
PTV6000
PTV5400
PTV5400
PTV6000 & PTV5400
PTV
Conventional dose radiotherapy arms
PTV5040
Kidney receiving higher dose Kidney_R or Kidney_L
Combined Kidneys
Liver Liver
Stomach Stomach
Small Bowel SmallBowel
Duodenum Duodenum
Spinal Cord PRV SpinalCord_05
aWhen the gastrointestinal tract overlaps with a planned target volume, there is sco
sparing. Abbreviations: PTV planned target volumean expansion of 0.5 cm around the GTV_C, edited off
the gastrointestinal tract. The PTV5040 and PTV5400
involve the CTV_3D with expansions of 0.5 cm cranial
(exhale breath-hold*) or 1.5 cm (free breathing), 1.5 cm
caudal, and 1.0 cm in ant-post and left-right direction.
The SIB (PTV6000) will be GTV_3D + 0.5 cm expansion
in all directions.
Participants receiving radiation at a standard dose
receive 50.4 Gy in 28 fractions (1.8 Gy per fraction) to
the PTV. They are treated once daily, five days per week,
using photon beams of ≥6 MV. Stage 2 participants in
the high-dose arms receive 54 Gy in 30 fractions (1.8 Gy
per fraction) to the PTV (PTV5400) and the SIB will be
delivered to the PTV6000 so that this volume receives a
total dose of 60 Gy in 30 fractions (2 Gy per fraction).
They are treated once daily, five days per week, using
photon beams of ≥6 MV. IMRT is mandated for the
high-dose arms and is preferred over 3D conformal
radiotherapy for the standard-dose arms. Table 2 gives
radiotherapy dose constraints.
The radiotherapy trials quality assurance (RTTQA)
programme was developed in collaboration with the
National Cancer Research Institute RTTQA group.Variable Optimal Mandatory
D99% ≥ 95% ≥ 90% (≥ 83%)a
D95% ≥ 97% ≥ 93% (≥ 90%)a
D99% ≥ 95% ≥ 90%
D95% ≥ 97% ≥ 93%
DMax (0.1 cc) ≤ 110% ≤ 115%
D99% ≥ 95% ≥ 90%
D95% ≥ 97% ≥ 93%
Dmax (0.1 cc) ≤ 105%. ≤ 107%
V20Gy ≤ 40% ≤ 45%
V20Gy ≤ 30% ≤ 35%
V30Gy – ≤ 30%
Mean ≤ 28Gy ≤ 30Gy
Dmax (0.1 cc) ≤ 58Gy ≤ 60Gy
V50Gy < 5 cc –
V45Gy < 75 cc –
Dmax (0.1 cc) ≤ 58Gy ≤ 60Gy
V50Gy < 10 cc –
V15Gy < 120 cc –
Dmax (0.1 cc) ≤ 58Gy ≤ 60Gy
V50Gy < 10 cc –
V15Gy < 60 cc –
Dmax (0.1 cc) – ≤ 45Gy
pe to reduce the dose in this region in order to prioritize gastrointestinal tract
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complete a benchmark exercise, including outlining and
planning cases. The RTTQA team reviews these cases
and provides detailed feedback. During the trial, the
team prospectively reviews the first two outlines and the
radiotherapy treatment plan for the first high and stand-
ard dose at each centre. The process is repeated for each
centre if there is an issue with the outlines or radiother-
apy plans, until there is a satisfactory submission. The
volumes and plans for all subsequent cases will be retro-
spectively reviewed.
Trial assessments
Screening
Participants are assessed at baseline for eligibility and all
participants undergo a CT scan of the thorax, abdo-
men, and pelvis or a PET-CT scan (≤4 weeks but not
> 6 weeks before starting induction chemotherapy).
CA19–9 assessments are performed for all partici-
pants before treatment begins.
On-trial
Participants are assessed clinically prior to each cycle of
chemotherapy and undergo a restaging CT scan after
three cycles of chemotherapy to determine post-induction
treatment eligibility. Post-induction participants receiving
chemoradiation (stage 1 and arms A-D of stage 2) are
assessed weekly during radiotherapy.
Assessments include weight, WHO performance sta-
tus, and treatment-related toxicity, as per CTCAE V4.03.
Haematology and biochemistry blood tests are undertaken
≤3 days before each chemotherapy dose and weekly during
chemoradiation. CA19.9 assessments are made four times
a week during chemotherapy. In the chemoradiation arms,
CA19.9 assessments are done before starting and 4–6
weeks after finishing chemoradiation.
Post-treatment
Restaging scans are undertaken 4–6 weeks after com-
pleting treatment. Suitable patients are referred for
surgery. Participants are followed-up every 10–12
weeks for the first year, with physical assessment,
CA19.9, and CT scans at each visit. Participants are
followed-up for at least 1 year, or until death (which-
ever is earlier). In each stage, follow-up will stop and
the trial completed once the last patient on study
reaches one year of follow-up.
Quality of life assessments
Stage 2 participants complete the European Organisation
for Research and Treatment of Cancer self-reported
questionnaires, QLQ-C30, PAN26, and EQ5D, at baseline;
either the start of chemoradiation or cycle 5 of GEBAMXchemotherapy, as per randomised group; the post-
treatment appointment; and follow-up appointments.
Safety reporting
Any adverse event (AE) that occurs from consent (Stage
1) or the first trial treatment dose (Stage 2) up to 30 days
after the last treatment dose are collected. AEs are
graded using the CTCAE V4.03. In both Stages, any
serious AE (SAE) from consent up to 30 days after the
last treatment dose are collected. Serious adverse reac-
tions (trial-treatment-related SAEs), will be collected
until the end of follow-up. Suspected unexpected serious
adverse reactions will be reported to the Medicines and
Health Care Product Regulatory Agency (MHRA).
Endpoints and outcome measures
Stage 1
Stage 1 determined the maximum tolerated dose of nel-
finavir for use in stage 2. Three nelfinavir doses were
tested: the starting dose of 1000mg twice-daily was
escalated to 1250 mg twice-daily or de-escalated to 750
mg twice-daily. The maximum tolerated dose was
defined as the highest nelfinavir dose administered
alongside chemoradiation at which none of three evalu-
able participants or no more than one of six evaluable
participants experienced a dose-limiting toxicity (DLT).
A DLT was defined as per CTCAE V4.03 during
chemoradiation and within 1 week post-chemoradiation
as: any toxicity grade ≥ 4, any non-haematological grade
3 nelfinavir- or treatment-related AE or laboratory
abnormality that the investigator deemed clinically sig-
nificant, an inability to tolerate at least 20 fractions of
radiotherapy due to an AE, or any SAE severe enough to
halt radiotherapy for ≥14 days before recommencement
(excluding events such as disease progression/stent
blockage). DLTs were assessed at weekly clinic visits
during and immediately after chemoradiation.
Stage 2
Stage 2 co-primary outcomes are 12-month OS rate
(radiotherapy dose-escalation question) and PFS time
(nelfinavir question). The 12-month OS rate is defined
as the number of participants who die within 12months
of registration over the number of participants in a
particular arm. PFS is defined as time (months) from
registration to radiological/clinical progression or death,
whichever occurs first. Participants who do not progress
or die during the course of the study will be censored at
their last known alive and progression-free date. Second-
ary outcomes include toxicity (as per CTCAE V4.03),
quality of life, disease response rate over follow-up, re-
section rate over follow-up, treatment compliance, and
CA19–9 response over follow-up.
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Stage 1 used the rolling-six design with three dose co-
horts and required up to 18 (6 per cohort) evaluable
participants.
Stage 2 plans to randomise 170 participants (34 per
arm). The sample size for the radiotherapy dose question
(50.4 Gy [arms A + B, n = 68] vs 60 Gy [arms C + D, n =
68]) is based on the maximum of two binomial random
variables and follows Dunnett’s ideas [24]. A 12-month
OS rate of 60% (the bottom of the 95% CI for 12-month
OS in SCALOP’s capecitabine-chemoradiation arm [1])
would not be large enough to warrant further investiga-
tion, whilst a rate of 80% is considered worthwhile. This
design is based on a one-sided 5% significance level and
a power of 90% of achieving significance if participants
on one novel treatment have a survival rate of 80% and
those on the second treatment a rate of 60%. A power
greater than 90% will be achieved if both treatments
have a worthwhile effect of 60%.
For the nelfinavir question, we assume median PFS
time for participants not taking nelfinavir to be 12
months [1]. The sample size is calculated to provide 90%
power to detect HR ≤ 0.65 with adding nelfinavir to
chemoradiation (arms A + C, n = 68), compared with re-
ceiving chemoradiation without nelfinavir (arms B + D,
n = 68), using a one-sided 20% significance level and as-
suming 5% loss to follow-up.
Sixty-five percent of SCALOP participants showed no
evidence of radiological progression after three cycles of
induction chemotherapy. We anticipated needing to
recruit 27 participants to stage 1 to ensure there were
up to 18 evaluable participants. We anticipate needing
to recruit 262 participants to stage 2 to ensure 170
randomised (34 per arm).
Statistical analysis
Stage 1 dose-level finding followed the rolling-six design.
All participants with DLTs were evaluable for dose-
escalation analysis. Participants without DLTs were eva-
luable if, during and ≤ 1 week after chemoradiation, they
received at least 80% of the total intended (starting) dose
of both nelfinavir and capecitabine, and at least 20
fractions of radiotherapy, and had completed the mini-
mum safety evaluation requirements at each weekly
clinic visit.
Stage 2 will use intention-to-treat based analyses, in-
cluding all randomised participants. For the primary
radiotherapy dose question: if 49 or more participants
survive on one radiotherapy arm, that arm will be taken
forward to a phase III trial. If both radiotherapy arms
have 49 or more participants surviving, survival, propor-
tion of participants completing the protocol dose
radiotherapy, and toxicities observed will be taken into
consideration to choose the treatment arm to takeforward. If fewer than 49 of the 68 participants survive
at 12 months on either treatment, no treatment will be
taken forward to a phase III trial. For the primary nelfi-
navir question, a log-rank test will compare the survival
curves between groups. The detailed statistical analysis
plan gives full explanations of all planned analyses for
primary, secondary, and tertiary aims.
Regulatory and monitoring committees
SCALOP-2 is conducted in accordance with the regula-
tory requirements for clinical trials and standard operat-
ing procedures. Data management is via the online
database system, OpenClinica, using electronic case re-
port forms and anonymised data is stored confidentially
at the Oxford Clinical Trials Research Unit. For stage 1,
the safety review committee, consisting of independent
clinical and medical oncologists, trial management
representatives, and trial statisticians, monitored and
reviewed the accumulated safety data and assigned
doses. In stage 2, a data safety and monitoring commit-
tee, consisting of independent oncologists and a statisti-
cian, will be responsible for data and safety monitoring
throughout the trial. It will first meet once 10 partici-
pants have completed high-dose radiotherapy treatment
and 10 participants have completed nelfinavir treatment.
Translational research
Blood samples and tumour biopsies are being collected
for future translational work from participants who
consent to take part in the translational part of the trial.
Blood and biopsies are collected at baseline, the start of
post-induction therapy, 4–6 weeks after ending post
-induction therapy, and at disease progression, and
stored at the Wales Cancer Bank, Cardiff University.
Discussion
SCALOP-2 will investigate the benefit of GEMABX
combination chemotherapy at induction, followed by
different chemoradiation schedules evaluating standard-
and high-dose radiotherapy with and without the
addition of the radiosensitiser nelfinavir. This phase II
2 × 2 factorial + 1 design will allow the two chemoradia-
tion research questions to be addressed efficiently. The
inclusion of a chemotherapy-only arm, using inter-
nationally approved combination chemotherapy, will
allow seamless progression to a phase III trial to for-
mally compare the best-performing trial arm(s).
It is widely acknowledged that pancreatic cancer is a
systemic disease. Chemoradiation’s role was brought into
question after the LAP07 trial showed no survival bene-
fit for chemoradiation over chemotherapy alone [3].
However, with greater understanding of tumour biology
and improved imaging such as PET-CT, it may be pos-
sible to identify tumours that are truly localised and
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important role. Proposed molecular markers defining
localised disease, like SMAD4, have been shown to be
evaluable in both biopsy and cytology samples [25]. Un-
derstanding the mechanisms that lead to radio-resistance
in pancreatic cancer and ways to overcome them will help
to define radiation’s role in managing this disease. The on-
going sample collection from stage 2 participants will
provide a large dataset with which to interrogate such
translational questions. Trial results will be published in
peer-reviewed journal(s) and presented at scientific
conferences.
In SCALOP-2, management permission (“R&D ap-
proval”) was sought from all NHS organisations involved
in the study, in accordance with NHS research govern-
ance arrangements, as listed here: Bristol University
Hospitals NHS Foundation Trust; Cambridge University
Hospitals NHS Foundation Trust; Colchester Hospital
University NHS Foundation Trust; Hull and East
Yorkshire Hospitals NHS Trust; Imperial College
Healthcare NHS Trust; NHS Grampian; Norfolk and
Norwich University Hospitals NHS Foundation Trust;
North Middlesex University Hospital NHS Trust;
Nottingham University Hospitals NHS Trust; Oxford
University Hospitals NHS Foundation Trust; Royal
Surrey County Hospital NHS Foundation Trust; Shef-
field Teaching Hospitals NHS Foundation Trust; The
Christie NHS Foundation Trust; The Leeds Teaching
Hospitals NHS Trust; The Royal Free London NHS
Foundation Trust; University College London Hospitals
NHS Foundation Trust; University Hospitals Coventry and
Warwickshire NHS Trust; University Hospitals Plymouth
NHS Trust; Velindre NHS Trust. SCALOP-2 is open to
international collaboration. Interested investigators are in-
vited to contact the trials unit (octo-scalop-2@oncolo-
gy.ox.ac.uk; 01865617078) for further discussion.
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